Heartland Advisors Inc. raised its position in Haemonetics Corporation (NYSE:HAE – Free Report) by 13.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 85,000 shares of the medical instruments supplier’s stock after acquiring an additional 10,000 shares during the period. Heartland Advisors Inc. owned about 0.18% of Haemonetics worth $4,791,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. North Peak Capital Management LLC boosted its holdings in Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after purchasing an additional 740,626 shares during the last quarter. Strs Ohio acquired a new stake in shares of Haemonetics in the fourth quarter valued at about $986,000. Horizon Investments LLC bought a new stake in Haemonetics during the fourth quarter worth about $2,398,000. M&T Bank Corp raised its holdings in Haemonetics by 205.9% during the fourth quarter. M&T Bank Corp now owns 14,370 shares of the medical instruments supplier’s stock worth $1,050,000 after acquiring an additional 9,673 shares in the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in Haemonetics during the fourth quarter worth about $2,293,000. Institutional investors and hedge funds own 99.67% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on HAE shares. Robert W. Baird set a $67.00 price target on Haemonetics in a research note on Friday, May 8th. BTIG Research reiterated a “buy” rating and set a $84.00 price objective on shares of Haemonetics in a research note on Friday, June 26th. Barrington Research decreased their target price on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and raised their target price for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Finally, Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $78.89.
Haemonetics Trading Up 0.1%
Shares of HAE stock opened at $77.97 on Monday. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The stock has a market cap of $3.54 billion, a P/E ratio of 38.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.52. The stock has a 50 day simple moving average of $70.49 and a 200 day simple moving average of $66.15. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.
Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, research analysts predict that Haemonetics Corporation will post 5.21 earnings per share for the current fiscal year.
About Haemonetics
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
See Also
- Five stocks we like better than Haemonetics
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
